Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

3(50.0%)

N/A

3(50.0%)

6Total

Phase 4(3)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05770622Phase 4Recruiting

Improving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2)

Role: collaborator

NCT06655207Not ApplicableRecruiting

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

Role: collaborator

NCT06901206Not ApplicableNot Yet Recruiting

Neonatologist-Performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy

Role: lead

NCT04044703Phase 4Completed

Improving Dosing of Vancomycin in Young Infants With Infections

Role: collaborator

NCT03034577Phase 4Completed

Deep Neuromuscular Block for Laparoscopic Surgery

Role: collaborator

NCT02210169Not ApplicableCompleted

RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates

Role: collaborator

All 6 trials loaded